Michael Prevoznik Net Worth

The estimated Net Worth of Michael E Prevoznik is at least $20.9 Million dollars as of 29 August 2024. Mr. Prevoznik owns over 32,551 units of Quest Diagnostics stock worth over $10,907,213 and over the last 21 years he sold DGX stock worth over $7,880,144. In addition, he makes $2,090,390 as Senior Vice President and General Counsel at Quest Diagnostics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Prevoznik DGX stock SEC Form 4 insiders trading

Michael has made over 51 trades of the Quest Diagnostics stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 32,551 units of DGX stock worth $3,118,386 on 29 August 2024.

The largest trade he's ever made was exercising 126,667 units of Quest Diagnostics stock on 17 June 2013 worth over $5,767,149. On average, Michael trades about 8,719 units every 51 days since 2004. As of 29 August 2024 he still owns at least 71,029 units of Quest Diagnostics stock.

You can see the complete history of Mr. Prevoznik stock trades at the bottom of the page.

Michael Prevoznik biography

Michael E. Prevoznik serves as Senior Vice President, General Counsel of the Company. Mr. Prevoznik joined the Company as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the U.S., and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business. Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.

What is the salary of Michael Prevoznik?

As the Senior Vice President and General Counsel of Quest Diagnostics, the total compensation of Michael Prevoznik at Quest Diagnostics is $2,090,390. There are 7 executives at Quest Diagnostics getting paid more, with Stephen Rusckowski having the highest compensation of $10,118,500.

How old is Michael Prevoznik?

Michael Prevoznik is 58, he's been the Senior Vice President and General Counsel of Quest Diagnostics since 2003. There are 11 older and 8 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.

Insiders trading at Quest Diagnostics

Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty, and Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.

What does Quest Diagnostics do?

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator

Complete history of Mr. Prevoznik stock trades at Quest Diagnostics

Quest Diagnostics executives and stock owners

Quest Diagnostics executives and other stock owners filed with the SEC include:

• Stephen Rusckowski,
  Chairman of the Board, President, Chief Executive Officer
• Manuel Mendez,
  Executive Officer
• Stephen H. Rusckowski,
  Chairman, Pres & CEO
• Mark Guinan,
  Chief Financial Officer, Executive Vice President
• James Davis,
  Executive Vice President, General Diagnostics
• Carrie Manner,
  Senior Vice President - Advanced Diagnostics
• Catherine Doherty,
  Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
• Michael Prevoznik,
  Senior Vice President, General Counsel
• James E. Davis,
  Exec. VP of Gen. Diagnostics
• Carrie Eglinton Manner,
  Sr. VP of Advanced Diagnostics
• Daniel Stanzione,
  Lead Independent Director
• Gary Pfeiffer,
  Independent Director
• Denise Morrison,
  Independent Director
• Gail Wilensky,
  Independent Director
• Timothy Main,
  Independent Director
• Timothy Ring,
  Independent Director
• Vicky Gregg,
  Independent Director
• Helen Torley,
  Independent Director
• Wright Lassiter,
  Independent Director
• Michael E. Prevoznik,
  Sr. VP & Gen. Counsel
• Mark J. Guinan,
  Exec. VP & CFO
• Gary D. Samuels,
  VP of Corp. Communications
• Timothy Sharpe,
  VP of Compliance
• Shawn C. Bevec,
  VP of Investor Relation
• Gabrielle Wolfson,
  Sr. VP and Chief Information & Digital Officer
• Michael J. Deppe,
  VP, Corp. Controller & Chief Accounting Officer
• Robert B Carter,
  Director
• Jeffrey M Leiden,
  Director
• Jenne K Britell,
  Director
• Robert A Klug,
  VP, Corporate Controller
• Everett Cunningham,
  SVP, Commercial
• John B Ziegler,
  Director
• Jon R Cohen,
  SVP and Chief Medical Officer
• William F Buehler,
  Director
• John B. Haydon,
  SVP, Operations
• Kathy Ordonez,
  SVP, Discovery & Development
• Robert Hagemann,
  Corp VP & Chief Fin Officer
• Surya N Mohapatra,
  President & COO
• Joan Elizabeth Miller,
  Sr VP -Pathology& HospServices
• John C Md Baldwin,
  Director
• Wayne R. Simmons,
  Vice President, Operations
• Rosanne Haggerty,
  Director
• Plc Gsk,
  10% owner
• Thomas W Ii Grant,
  Executive Officers
• William R Grant,
  Director
• Thomas F Bongiorno,
  Vice President and Controller
• James F Iii Flaherty,
  Director
• David M Zewe,
  Sr. VP -Diagnostic Testg Ops
• Robert E Peters,
  Vice President, Sales & Mktg.
• Kenneth W/Nj Freeman,
  Chairman, Chief Exec Officer
• Mary A Cirillo,
  Director
• Kenneth D Brody,
  Director
• Gerald C Marrone,
  Sr. VP, Administration
• Luis Diaz,
  Director
• Tracey Doi,
  Director
• Michael J Deppe,
  SVP, Corp. Controller & CAO
• Sam Samad,
  Executive Vice President & CFO
• Patrick Plewman,
  SVP for Diagnostic Services
• Karthik Kuppusamy,
  SVP, Clinical Solutions
• J. E. Davis,
  CEO and President
• Mark E Delaney,
  SVP & Chief Commercial Officer
• Mark A Gardner,
  SVP of Molecular Gen & Oncol